SLC46A2 and psoriasis: Methotrexate is also a commonly used therapeutic agent in psoriasis; its anti-psoriasis mechanism is complex and includes inhibitory effects on folate-dependent enzyme, NF-κB, lincRNA-p21, NO synthase, and solute-carrier family 46 member 2 (SLC46A2) [58].